Gilead Sciences Inc

Add good karma to your portfolio with GILD. This research-based biopharmaceutical company is making the world a better place by developing and commercializing medicines for life-threatening diseases like HIV/AIDS, liver diseases, and cancer. Gilead’s HIV treatments, including Truvada and Atripla, have helped transform the chronic disease into a manageable condition. Their treatments are responsible for saving millions of lives.

$112.08
(as of Apr 4, 9:47 AM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Gilead Sciences Inc

Stock Price
$112.08
Ticker Symbol
GILD
Exchange
NASDAQ

Industry Information for Gilead Sciences Inc

Sector
Healthcare
Industry
Drug Manufacturers - General

Company Description for Gilead Sciences Inc

Country
USA
Full Time Employees
17,600

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Fundamentals for Gilead Sciences Inc

Market Capitalization
$139,485,429,760
EBITDA
$13,454,000,128
Dividends per Share
$3.08
P/E Ratio
294.45
Forward P/E Ratio
14.16
Earnings per Share
$0.38
Earnings per Share Estimate Next Year
Profit Margin
1.67%
Shares Outstanding
1,246,630,016
Percent Owned by Insiders
0.12%
Percent Owned by Institutions
89.59%
52-Week High
52-Week Low

Technical Indicators for Gilead Sciences Inc

50-Day Moving Average
200-Day Moving Average
RSI
59.52
2.53

Analyst Ratings for Gilead Sciences Inc

Strong Buy
13
Buy
4
Hold
11
Sell
0
Strong Sell
0

News About Gilead Sciences Inc

Apr 3, 2025, 5:50 PM EST
In the latest market close, Gilead Sciences (GILD) reached $112.39, with a +0.45% movement compared to the previous day. See more.
Apr 2, 2025, 6:00 PM EST
Gilead Sciences (GILD) ended the recent trading session at $111.88, demonstrating a +0.54% swing from the preceding day's closing price. See more.
Apr 2, 2025, 9:40 AM EST
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. See more.
Apr 2, 2025, 9:00 AM EST
Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. See more.